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Abstract
We investigated the optimal combinations of systolic blood pressure (SBP) and dias-
tolic blood pressure (DBP) levels for lowest mortality in participants not taking hyper-
tensive medication at the study baseline using nationwide representative databases. 
Survival rates and hazard ratios (HRs) were calculated using Kaplan-Meier curves and 
multivariable Cox regression analyses. The discriminatory ability for clinical outcomes 
was assessed by Harrell's C-index analysis. A survival spline curve was presented, and 
Classification and Regression Tree (CART) analysis was performed. SBP ≥ 140 group 
and DBP ≥ 90 group had the highest risk of mortality. Within SBP < 120, the HR (95% 
CIs) for all-cause mortality (ACM) was the lowest for DBP 70-79. Within SBP 120-139, 
the HR (95% CIs) for ACM was significantly lower for DBP 70-79. Within SBP ≥ 140, 
the HR (95% CIs) for ACM was significantly lower for DBP 80-89. Conversely, within 
SBP ≥ 140, DBP < 70 showed the highest risk for ACM. Similar relationships were 
observed when survival spline curves and CART analysis were used. The combination 
of SBP and DBP discriminated better than SBP or DBP alone for mortality. The effect 
of DBP on mortality varies according to the SBP range. It is more effective to evaluate 
the effect of SBP and DBP jointly for clinical outcomes.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in 
any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2020 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC
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1  |  INTRODUC TION
Hypertension is a well-established major risk factor for cardio-
vascular morbidity and mortality.1 Largely based on the results of 
SPRINT (Systolic Pressure Intervention Trial), the 2017 American 
College of Cardiology/American Heart Association (AHA/ACC) 
guideline changed the landscape for blood pressure (BP) control 
goals, with a new definition for hypertension starting at a BP of 
130/80 mmHg.2 The new guideline additionally recommends an-
tihypertensive medication for adults at high risk of cardiovascular 
disease (CVD) with SBP 130-139 mmHg or DBP 80-89 mmHg. This 
is supported by the recent large-scale systematic reviews and me-
ta-analyses that intensive BP lowering is beneficial in reducing CV 
outcomes, especially for those with high CV risk.3 However, con-
flicting reports still exist. Intensive BP lowering is associated with 
increased incidence of treatment-associated adverse events, and 
several studies suggest that achieving both SBP < 120 mmHg and 
DBP < 70 mmHg increases the risk of cardiovascular events.4 In ad-
dition, strict BP lowering in the elderly was significantly associated 
with myocardial infarction and chronic heart failure.5,6 Unlike SBP, 
the J-curve phenomenon between low DBP and cardiovascular 
events has been reported.7
Most recent studies have independently examined the effects of 
SBP or DBP on clinical outcomes, and few studies have considered 
SBP and DBP levels concurrently. Therefore, we hypothesized that 
ideal combinations of SBP and DBP levels would differ according 
to BP level. We investigated the optimal combinations of SBP and 
DBP levels to decrease all-cause and cardiovascular mortality in 
middle-aged and elderly adults using nationwide representative da-
tabases. To analyze long-term blood pressure control and its effects, 
we selected participants who were not diagnosed with hypertension 
and did not take hypertensive medication at the baseline of the study.
2  |  METHODS
2.1  |  Study population and data collection
This study used data obtained from the National Health Insurance 
System–National Health Screening Cohort (NHIS-HEALS), a na-
tional retrospective cohort study conducted by the Korea Centers 
for Disease Control and Prevention. The NHIS is a universal health 
coverage program, and all insured individuals and their dependents 
are required to undergo general health examinations every 2 years. 
Study populations were followed from January 1, 2006, until the 
date of a cardiovascular event, death, or December 31, 2015, which-
ever came first.
We extracted 1 021 208 participants whose data were avail-
able and excluded individuals who met any of the following criteria: 
younger than 40 or older than 75 years of age; history of hospital-
ization for a diagnosis of myocardial infarction (MI; Korean Standard 
Classification of Diseases, KCD codes I21-I23) or stroke (KCD codes 
I60-I64); any type of malignant cancer; death in the year of enroll-
ment; single medical record after 2006; and those with missing SBP, 
DBP, or death data. Hypertension was defined as having a record 
of prescriptions for antihypertensive medications or diagnosis of 
hypertension (KCD codes I10-I13). Participants who had prescrip-
tion records for antihypertensive medications were also excluded. 
Following these exclusions, 79 983 participants were included in the 
final analysis (Figure 1).
Blood pressure was measured at local hospitals and clinics, each 
of which met the internal and external quality control procedures 
of the Korean Association of External Quality Assessment Service. 
After 5 minutes of rest in the sitting position, BP measurements were 
taken by digital or automatic monitors during the health examination. 
If the SBP measurement was > 120 mmHg, or the DBP > 80 mmHg, 
F I G U R E  1  Flow chart of the study population
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BP was measured repeatedly. All BP measurements, including BP 
data before the index period, were used to calculate mean BP.
Self-reported physical activity, cigarette smoking, and alcohol 
consumption were determined from questionnaires. Physical activ-
ity was divided into five groups: 0, 1-2, 3-4, 5-6, and “almost every 
day” according to the number of days of exercise during the week. 
Current smokers were classified as smokers. Alcohol drinkers were 
categorized as non-drinker, intermittent drinker (≤3-4 times a week), 
or daily drinker. Household income is divided into five groups based 
on decile data from the NHIS-HEALS dataset.
The study was approved by the Institutional Review Board of 
Yonsei University Health System (IRB number: 3-2018-0160), and 
the requirement for informed consent was waived.
2.2  |  Outcome measurement
The primary outcomes of the study were all-cause mortality (ACM) 
and all cardiogenic mortality. All cardiovascular death (ACD) was de-
fined as death from a disease of the circulatory system (KCD codes 
I00-I99). We selected MI (KCD codes I21-I23), hemorrhagic stroke 
(KCD codes I60-I62), and ischemic stroke (KCD code I63) among the 
detailed causes of cardiovascular mortality and named it as major 
cardiovascular death (MACE).
2.3  |  Statistical analysis
Systolic blood pressure and DBP were classified into 4 groups. For 
SBP groups, <120, 120-129, 130-139, and ≥ 140 were categorized. 
For DBP groups, <70, 70-79, 80-89, and ≥ 90 were categorized. We 
performed analyses of combinations of SBP and DBP, more specifi-
cally by categorizing DBP groups within the same SBP group. For 
example, the SBP < 120 mmHg group was subdivided into 4 groups 
according to DBP as follows: SBP < 120/DBP < 70, SBP < 120/DBP 
70-79, SBP < 120/DBP 80-89, and SBP < 120/DBP ≥ 90.
The characteristics of the study population were compared using 
one-way analysis of variance (ANOVA) for continuous variables and 
the chi-squared test for categorical variables, respectively.
The survival rates of each group according to the adjustment cri-
teria presented in each BP group were analyzed by Kaplan-Meier 
curve and log-rank test. Hazard ratios (HRs) and 95% confidence 
intervals (CIs) were calculated according to BP levels using multi-
variable Cox regression analysis after adjusting for age, sex, BMI, 
physical activity, household income, smoking status, alcohol status, 
fasting glucose, and total cholesterol.
Harrell's C-index analysis was performed to evaluate the discrim-
ination ability of SBP, DBP, and combination BP status. A survival 
spline curve was presented, and Classification and Regression Tree 
(CART) analysis was performed.
All statistical analyses were performed using SAS software, ver-
sion 9.4 (SAS Institute Inc, Cary, NC, USA), which incorporates sam-
ple weights and adjusts for the complex sample design of the survey. 
All statistical tests were two-sided, and statistical significance was 
determined at p < .05.
3  |  RESULTS
Table 1 presents baseline characteristics according to SBP and 
DBP. At baseline in 2006, 23% (n = 23 898) of participants had a 
previous hypertension diagnosis and were taking antihypertensive 
F I G U R E  2  Kaplan-Meier curves and log-rank test for all-cause death, all cardiovascular death, and major cardiovascular death according 
to blood pressure (BP) groups
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medications, and 77% (n = 79 983) of participants had no hyper-
tension history. There was a significant difference in all variables 
between participants taking antihypertensive medications or not. 
As SBP and DBP increased, participants not taking medication for 
hypertension at the study baseline tended to be older, men, current 
smokers, consumed more alcohol, had a higher BMI, and had higher 
fasting glucose, total cholesterol, and liver function enzymes.
Figure 2 shows the cumulative incidence of the three outcomes: 
ACM, ACD, and MACE (acute myocardial infarction, ischemic 
strokes, hemorrhagic strokes) according to BP using Kaplan-Meier 
curves and log-rank test. A total of 2549 ACM, 367 ACD, and 185 
MACE events occurred during follow-up. There was a significant 
linear trend toward an increased risk of all three outcomes, with 
worse SBP and DBP control. As a result, the SBP ≥ 140 and 
DBP ≥ 90 groups had the highest risk of mortality. Within the same 
SBP levels, we analyzed the risk of mortality according to DBP levels 
(Figure 3). For SBP 120-129, ACM was higher in the DBP ≥ 90 group. 
Within the SBP 130-139 and ≥ 140 groups, ACM was higher in the 
DBP < 70 group.
Tables 2, 3, and 4 show HRs (95% CIs) for ACM, ACD, and MACE 
according to separated SBP and DBP groups or combinations of SBP 
and DBP groups after adjusting for age, sex, BMI, physical activity, 
household income, smoking status, alcohol status, fasting glucose, 
and total cholesterol. Because SBP is more discriminating than DBP, 
F I G U R E  3  Kaplan-Meier curves and log-rank test for all-cause death, all cardiovascular death, and major cardiovascular death according 
to DBP levels within the same SBP levels. DBP, diastolic blood pressure; SBP, systolic blood pressure
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we performed SBP and DBP combination analysis by categorizing 
DBP groups within the same SBP group.
Table 2 shows the HRs (95% CIs) for ACM analysis. The HR (95% 
CIs) was highest for the SBP ≥ 140 and DBP ≥ 90 groups, and this trend 
was similar in ACD and MACE analyses. Similar relationships were ob-
served when survival spline curves were used to treat SBP and DBP as 
continuous variables (Figure 4). SBP higher than 120 mmHg was asso-
ciated with a risk for all three outcomes in a dose-responsive manner. 
Similarly, DBP higher than 70 mmHg gradually increased the risk of 
clinical outcomes. Within SBP < 120, the HR (95% CIs) for ACM was 
lowest in the DBP 70-79 group, followed by the DBP < 70, DBP 80-89, 
and DBP ≥ 90 groups. Within SBP 120-139, the HR (95% CIs) for ACM 
was significantly lower in the DBP 70-79 group. Within SBP ≥ 140, the 
HR (95% CIs) for ACM was significantly lower in the DBP 80-89 group. 
Conversely, within SBP ≥ 140, the DBP < 70 group showed the highest 
risk for ACM. In other words, the effect of DBP on ACM varies accord-
ing to the range of SBP.
We observed a similar trend in ACD analysis. As for ACM, HRs 
(95% CIs) for ACD were highest for the SBP ≥ 140 and DBP ≥ 90 
groups. Within the SBP < 120 and SBP 120-129 groups, the HRs 
(95% CIs) for ACD were significantly lower in the DBP < 70 group. 
But within the SBP 130-139 and SBP ≥ 140 groups, the HRs (95% CIs) 
for ACD showed the lowest risk in the DBP 70-79 group. Consistent 
with the ACM analysis, the DBP < 70 group showed the highest risk 
for ACD within the SBP ≥ 140 group. (Table 3).
Table 4 shows HR (95% CIs) analysis for MACE. HRs (95% CIs) 
for MACE were highest for the SBP ≥ 140 and DBP ≥ 90 groups. 
The DBP 70-79 group showed the lowest HRs (95% CIs) for MACE 
in all SBP ranges. As in the two analyzes described above, the 
DBP < 70 group showed the highest risk for MACE within the 
SBP ≥ 140 group.
To evaluate the potential discriminatory ability of SBP, DBP, 
and SBP and DBP in combination for clinical outcomes, Harrell's 
C-indexes were calculated (Table 5). These results suggest that 
SBP alone and the combination of SBP and DBP are more discrim-
inating than DBP alone in all three outcomes. In ACM analysis, 
the combination of SBP and DBP discriminated better than SBP 
alone. But in ACD and MACE analyses, there was no difference in 
discrimination ability between SBP alone and the combination of 
SBP and DBP.
Groups HR (95% CI) Pairwise comparison p-Value
SBP <120 0.633 (0.557-0.72) <.001 .212 .003
120 ~ 129 0.539 (0.477-0.61) <.001 .129 ref
130 ~ 139 0.588 (0.518-0.668) <.001 ref
≥140 1 ref
DBP <70 0.529 (0.445-0.629) <.001 .490 <.001
70 ~ 79 0.39 (0.337-0.452) <.001 <.001 ref
80 ~ 89 0.505 (0.436-0.586) <.001 ref
≥90 1 ref
SBP < 120 DBP < 70 0.043 (0.003-0.71) .028 .003 .005
70 ~ 79 0.035 (0.002-0.568) .018 <.001 ref
80 ~ 89 0.077 (0.005-1.292) .075 ref
≥90 1 ref
120 ~ 129 DBP < 70 0.346 (0.124-0.968) .043 .662 .025
70 ~ 79 0.242 (0.09-0.648) .005 <.001 ref
80 ~ 89 0.322 (0.119-0.866) .025 ref
≥90 1 ref
130 ~ 139 DBP < 70 0.644 (0.295-1.404) .269 .896 .401
70 ~ 79 0.475 (0.323-0.697) <.001 .011 ref
80 ~ 89 0.615 (0.431-0.875) .007 ref
≥90 1 ref
≥140 DBP < 70 1.603 (0.395-6.502) .509 .158 .218
70 ~ 79 0.655 (0.463-0.926) .017 .521 ref
80 ~ 89 0.586 (0.477-0.72) <.001 ref
≥90 1 ref
Note: Adjusted for age, sex, BMI, physical activity, household income, smoking status, alcohol 
status, fasting glucose, total cholesterol.
Abbreviations: DBP, diastolic blood pressure; SBP, systolic blood pressure.
TA B L E  2  Hazard ratios for all-cause 
death according to blood pressure groups
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According to the result of Harrell's C-indexes, we performed 
CART analysis, considering the joint effects of SBP and DBP simul-
taneously for the lowest mortality (Figure 5). In ACM analysis, re-
gardless of DBP, the SBP < 120 group had low risk and SBP ≥ 140 
had high risk. Prognosis was poor in the SBP 120-129 group when 
DBP was < 70 and ≥ 90, and in the SBP 130-139 group when DBP 
was < 70. In the ACD analysis, as in the ACM analysis, the SBP < 120 
group had low risk and SBP ≥ 140 had high risk regardless of DBP. 
The SBP 120-129 group showed poor prognosis with DBP ≥ 90, 
and SBP 130-139 showed poor prognosis with DBP < 70 and ≥ 90. 
In MACE analysis, there was no cut-off value of poor prognosis in 
SBP < 120, 120-129, and 130-139. Poor prognosis in the SBP ≥ 140 
group was when DBP < 70.
4  |  DISCUSSION
The 2017 ACC/AHA guideline emphasized strict BP control and 
recommended to reduce SBP/DBP < 130/80 mmHg.2 The 2018 
European Society of Cardiology/European Society of Hypertension 
(ESC/ESH) guidelines maintain the diagnostic threshold of hy-
pertension at 140/90 mmHg and redefined office BP treatment 
targets according to age stratification and CV risk profiles.8 It is 
still unknown whether excessive BP reduction results in improved 
clinical outcomes. Previous studies did not account for the com-
plex relationships between BP components and mortality. We ex-
amined the effects of SBP and DBP on mortality simultaneously, 
rather than assessing each BP component separately. Although 
high BP (SBP ≥ 140 and DBP ≥ 90) has a poor prognosis and is 
consistent with the results of previous experiments, prognosis 
was poor in the SBP 120-129 group when DBP was < 70 and ≥ 90, 
and in the SBP 130-139 group when DBP was < 70. In addition, 
the lowest risk of DBP was 70-79, not < 70, with a J-shape in the 
spline curve analysis, meaning it is more effective and appropriate 
to evaluate the effect of SBP and DBP jointly in clinical outcomes. 
This is supported by our Harrell's C-index analysis, and the com-
bination analysis showed higher discrimination ability than that of 
SBP or DBP alone.
Previous studies have shown similar results. Glynn et al (2000) 
showed the lowest mortality at SBP ≤ 130 and DBP 80-90, and 
Groups HR (95% CI) Pairwise comparison p-Value
SBP <120 0.301 (0.215-0.42) <.001 .152 .136
120 ~ 129 0.381 (0.286-0.507) <.001 .954 ref
130 ~ 139 0.384 (0.284-0.52) <.001 ref
≥140 1 ref
DBP <70 0.155 (0.093-0.258) <.001 <.001 .0914
70 ~ 79 0.229 (0.165-0.318) <.001 <.001 ref
80 ~ 89 0.372 (0.269-0.513) <.001 ref
≥90 1 ref
SBP < 120 DBP < 70 0.003 (0.001-0.059) <.001 .004 .087
70 ~ 79 0.005 (0.001-0.095) <.001 .033 ref
80 ~ 89 0.013 (0.001-0.315) .007 ref
≥90 1 ref
120 ~ 129 DBP < 70 0.142 (0.016-1.296) .084 .163 .931
70 ~ 79 0.149 (0.02-1.093) .061 .001 ref
80 ~ 89 0.298 (0.04-2.199) .235 ref
≥90 1 ref
130 ~ 139 DBP < 70 0.257 (0.031-2.103) .205 .882 .952
70 ~ 79 0.241 (0.104-0.562) .001 .421 ref
80 ~ 89 0.299 (0.14-0.639) .002 ref
≥90 1 ref
≥140 DBP < 70 3.255 (0.441-24.012) .247 .085 .077
70 ~ 79 0.487 (0.215-1.104) .085 .719 ref
80 ~ 89 0.564 (0.366-0.87) .010 ref
≥90 1 ref
Note: Adjusted for age, sex, BMI, physical activity, household income, smoking status, alcohol 
status, fasting glucose, total cholesterol.
Abbreviations: DBP, diastolic blood pressure; SBP, systolic blood pressure.
TA B L E  3  Hazard ratios for all 
cardiovascular death according to blood 
pressure groups
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the highest mortality at SBP > 160 and DBP < 70.9 In a recent 
study, patients with atrial fibrillation (AF) undergoing hypertension 
treatment showed a U-shaped relationship of major cardiovascu-
lar events, with SBP 120-129 and DBP < 80 mmHg as the optimal 
BP treatment target.10 Several studies suggested that 70 mmHg 
was the optimal DBP target and an increased risk of death for 
DBP ≤ 70 mmHg, especially in the elderly.11,12 Recently, our group 
found that participants in the DBP < 70 mmHg group who took hy-
pertension drugs had a high risk of mortality regardless of SBP sta-
tus, and the highest mortality was observed in the DBP < 70 mmHg 
and SBP ≥ 140 mmHg groups.13
Although the precise mechanism for the relationship between 
SBP, DBP, and mortality remains unknown, this could be partly ex-
plained by pulse pressure (PP). PP is higher due to the tendency of 
SBP to increase and DBP to decrease with age, which is attributed 
to a loss of arterial wall elasticity and arterial stiffness.14 Apart from 
high BP, wide PP is also known to increase cardiovascular or all-
cause mortality.15 The association between PP and CVD incidence 
was previously reported by Blacher et al, in which hypertensive 
patients had a 17% increased risk of CVD per 10 mmHg higher 
PP.16 However, PP alone, without appropriate attention to SBP 
and DBP components, is an inadequate risk indicator for prognos-
tic and therapeutic decisions.17 Increasing PP by increasing SBP 
was consistently associated with increased risk, while increasing 
PP by decreasing DBP could be associated with increased risk, de-
creased risk, or no change in risk depending on age and BP level.17 
Similarly in our results, for a fixed DBP, increasing PP by increasing 
SBP was associated with higher mortality, while decreasing PP by 
increasing DBP above 90 mmHg increased risk for death. Overall, 
our observations emphasize that PP in conjunction with SBP and 
DBP might be effective to identify patients at high risk of CVD and 
all-cause mortality. Future clinical studies are needed to validate 
these findings.
There are some limitations in this study. First, because the 
current study was an observational study, potentially unmea-
sured confounding factors could overestimate or underestimate 
the impact of BP on clinical outcomes. Second, although BP-
measuring equipment of all health examination institutions is 
Groups HR (95% CI) Pairwise comparison p-Value
SBP <120 0.197 (0.121-0.319) <.001 .120 .023
120 ~ 129 0.335 (0.229-0.489) <.001 .540 ref
130 ~ 139 0.294 (0.193-0.447) <.001 ref
≥140 1 ref
DBP <70 0.08 (0.034-0.191) <.001 .001 .02
70 ~ 79 0.211 (0.136-0.327) <.001 .004 ref
80 ~ 89 0.344 (0.224-0.53) <.001 ref
≥90 1 ref
SBP < 120 DBP < 70 0.001 (0.001-0.011) <.001 .005 .029
70 ~ 79 0.001 (0.001-0.035) <.001 .098 ref
80 ~ 89 0.004 (0.001-0.136) .002 ref
≥90 1 ref
120 ~ 129 DBP < 70 0.264 (0.013-5.467) .389 .760 .504
70 ~ 79 0.179 (0.01-3.106) .238 .042 ref
80 ~ 89 0.316 (0.018-5.533) .431 ref
≥90 1 ref
130 ~ 139 DBP < 70 0.358 (0.016-8.042) .518 .995 .972
70 ~ 79 0.34 (0.094-1.225) .099 .873 ref
80 ~ 89 0.361 (0.112-1.162) .088 ref
≥90 1 ref
≥140 DBP < 70 2.814 (0.155-51.063) .484 .270 .212
70 ~ 79 0.4 (0.126-1.276) .122 .582 ref
80 ~ 89 0.552 (0.315-0.967) .038 ref
≥90 1 ref
Note: Adjusted for age, sex, BMI, physical activity, household income, smoking status, alcohol 
status, fasting glucose, total cholesterol.
Abbreviations: DBP, diastolic blood pressure; SBP, systolic blood pressure.
TA B L E  4  Hazard ratios for major 
cardiovascular death according to blood 
pressure groups
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quality-qualified according to the Basic Act on National Health 
Examination, a lack of device uniformity and single visit mea-
surements may have caused slight variability within results. 
However, recent guidelines have advocated that single visit mea-
surements with automatic office-based devices represent a less 
resource-intensive yet equally or more precise measurement of 
BP than multiple clinic visits.18 Third, our study participants are 
all Korean adults, so the results may not be generalized to other 
races or ethnic groups. Fourth, some of the 16 categories had 
small sample and event sizes, potentially limiting their statis-
tical accuracy. Further research is needed with a larger sample 
size. Nevertheless, this study has several strengths. We used a 
large-scale Asian cohort in a real-world setting from the National 
Health Insurance System–National Health Screening Cohort 
(NHIS-HEALS), a reliable large national data set sampled from 
most adult health insurance subscribers in Korea. We also used 
various statistical approaches to adjust for multiple types of bias 
and improve the accuracy of predictive survival models with SBP 
and DBP in combination.
Taken together, the results are summarized as follows. High 
BP (SBP ≥ 140 and DBP ≥ 90) has a poor prognosis and is con-
sistent with the results of previous experiments. However, lower 
BP does not always yield a better prognosis. With SBP 130 as the 
boundary, high DBP with lower SBP, and low DBP with higher SBP, 
showed high risk for mortality. In particular, the lowest DBP (<70) 
had a worse prognosis than other groups with the highest SBP. 
This study used a statistical model to examine a new perspective 
using a statistical model. If clinical research supports these find-
ings, primary care providers may consider the optimal combina-
tion of SBP and DBP, rather than SBP or DBP alone, in clinical 
decision-making.
F I G U R E  4  Survival spline curve for all-cause mortality, all cardiovascular death, and major cardiovascular death according to blood 
pressure (BP) groups
TA B L E  5  Discrimination ability for all-cause death, all 
cardiovascular death and major cardiovascular death according to 
systolic blood pressure




DBP 0.542(0.529-0.553) <0.001 ref
SBP + DBP 0.588(0.576-0.6) 0.008 <0.001
ACD
SBP 0.668(0.636-0.7) ref
DBP 0.628(0.601-0.659) <0.001 ref
SBP + DBP 0.667(0.635-0.7) 0.739 0.003
MACE
SBP 0.7(0.661-0.739) ref
DBP 0.659(0.617-0.739) 0.008 ref
SBP + DBP 0.699(0.662-0.737) 0.617 0.012
Abbreviations: ACD, all cardiovascular death; ACM, all causes mortality; 
C-index, Concordance-index; MACE, major cardiovascular death.
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